Text and Data Mining valid from 2020-02-17
Received: 29 March 2019
Accepted: 5 February 2020
First Online: 17 February 2020
Ethics approval and consent to participate
: The study was approved by the local Ethics Committee (Reference No. 1508–1997) of the Hannover Medical School (MHH), Hanover, Germany. All participants signed written informed consent.
: Not applicable.
: The authors of this manuscript have the following competing interests: DED and HL held non-licensed common patents on a 2nd indication of amantadine (Germany, USA, China, and Japan) which are expired. HL held non-licensed patents on BDV diagnostic procedures (Germany and USA) which are also expired. HL received personal consulting fees from medical laboratories in Germany, Diamedis (ExternalRef removed) and DEDIMED (ExternalRef removed). LB and HL report a common patent application on differential BDV-1 diagnosis (first publication on 11th April, 2019) by the German Patent and Trade Mark Office), and personal fees from R-Biopharm (ExternalRef removed). CWS is a full-time employee of Idorsia Pharmaceuticals (Allschwil, Switzerland). HH and HME declared they have no competing interests.